Evidence map›Paper›PMID 41215973›Full record

ArticlePNAS nexus2025

Increase of Inhibitory Siglec receptors on T cells mitigates severe immune reactions during acute viral infections.

Natalia Rodrigues Mantuano, Anne Bärenwaldt, Mirza Sarcevic, Isabelle V M Siqueira, Annaïse Jauch, Manina Maja Etter, Matthias S Matter, Gregor Hutter, Mike Recher, Heinz Läubli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natalia Rodrigues MantuanoDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-1302-7013
Anne BärenwaldtDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0001-5800-3747
Mirza SarcevicDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
Isabelle V M SiqueiraDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
Annaïse JauchDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
Manina Maja EtterDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-2889-8305
Matthias S MatterDepartment of Pathology, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-2005-5266
Gregor HutterDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-7570-3902
Mike RecherDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-9121-6936
Heinz LäubliDepartment of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID https://orcid.org/0000-0002-8910-5620

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of inhibitory Siglec receptors has been described on T cells of patients with viral infection and cancer. However, the exact function and their role in T-cell activation and control of infections have not been well investigated. Here, we show that Siglec-9 levels increase on T cells in patients with acute severe acute respiratory syndrome coronavirus 2 infection relative to levels on healthy controls. T cells of these patients are inhibited by Siglec-9, and specific blocking with antibodies released this inhibition. To further test the role of Siglec-9 in acute viral infections, we characterized a murine model with T-cell intrinsic Siglec-9 overexpression. We found that Siglec-9 restricted T-cell immunity after acute infection with lymphocytic choriomeningitis virus, thereby dampening T-cell-mediated immune pathology. These results show that inhibitory Siglec receptors including Siglec-9 T cell intrinsically modulate and fine-tune antiviral T-cell activation, proliferation, and effector function.

Indexed as

COVID-19immune checkpointinhibitory receptorSARS-CoV-2T cell

Identifiers

PMID41215973
PMCPMC12596597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.